Reporting and Data Sample Clauses

Reporting and Data. Demonstrate the ability to maintain accurate, reliable, and timely data entry into the statewide early intervention database that accurately tracks each child served in Utah’s early intervention system. This will allow for timely and accurate reporting in alignment with state and federal reporting requirements.
Sample 1Sample 2
AutoNDA by SimpleDocs
Reporting and Data a. The Beneficiary will prepare and provide a progress report which captures activities, outputs and outcomes identified in the Work Plan as required by the County, and metrics from the 2021-2026 Douglas County Public Health Improvement plan if indicated, on a bi-annual basis, by July 30th for January to June activities, and by January 31st for July to December activities. The Beneficiary is required to report only activities, outputs and outcomes related to the funding received. The Beneficiary shall also prepare and provide a progress report ahead of contract renewal, if applicable, by October 31st each year. b. The Happy Crew is a Beneficiary of ARPA Revenue Replacement funds. Treasury Guidance (SLFRF Final Rule FAQs) indicate that, “Treasury is not collecting subaward data for projects categorized under Expenditure Category Group 6, “Revenue Replacement.” Treasury has determined that there are no subawards under this eligible use category. The Beneficiary acknowledges that these reduced reporting standards are subject to change at the discretion of the US Department of Treasury, and agrees to provide such financial, performance, compliance reporting and/or records in such form as may be requested by the County. For this Contract, Douglas County staff shall: A. Schedule, at a minimum, twice a year check-ins with the Beneficiary, or as needed to address any Beneficiary questions, or issues as they arise, for example, billing, reporting, etc. B. Oversee contract management to include oversight and adherence to terms, reporting, amendments, and contract renewal.
Sample 1
Reporting and Data. (a) Upon request, ** shall promptly, but in no event later than thirty (30) days after such request provide Fidopharm with (i) a summary in reasonable detail of all data generated or obtained from each discrete Development activity performed under the Development Plan, such as any toxicology study, pharmacokinetics study or stability study, (ii) a summary of the Development progress against the projected Development progress set forth in the current Development Plan and (iii) a final report of the results of each Development activity, together with all material supporting data. (b) shall provide Fidopharm copies of all substantive or material information with respect to the Development of Products, including clinical data compiled with respect to Products and all information and data filed with any governmental authority with respect to Products outside of the Territory, as soon as reasonably practicable after such information, data or results become available to or compiled by **, including any drafts and final versions of any study reports (the “Development Data”). Subject to the terms and conditions of this Agreement, Fidopharm shall have the right to use the Development Data or any portion thereof for the purpose of obtaining Product Registrations and commercializing Products in the Territory.
Sample 1
Reporting and Data. (a) Upon request, Omnipharm shall promptly, but in no event later than thirty (30) days after such request provide Fidopharm with (i) a summary in reasonable detail of all data generated or obtained from each discrete Development activity performed under the Development Plan, such as any toxicology study, pharmacokinetics study or stability study, (ii) a summary of the Development progress against the projected Development progress set forth in the current Development Plan and (iii) a final report of the results of each Development activity, together with all material supporting data. (b) Omnipharm shall provide Fidopharm copies of all substantive or material information with respect to the Development of Products, including clinical data compiled with respect to Products and all information and data filed with any governmental authority with respect to Products outside of the Territory, as soon as reasonably practicable after such information, data or results become available to or compiled by Omnipharm, including any drafts and final versions of any study reports (the “Development Data”). Subject to the terms and conditions of this Agreement, Fidopharm shall have the right to use the Development Data or any portion thereof for the purpose of obtaining Product Registrations and commercializing Products in the Territory.
Sample 1
Reporting and Data. Commencing on the Effective Date: a. SCI shall provide weekly reports of process quality performance, including yield, defect pareto, root cause, and corrective actions. Process steps to be included in the reports are to be mutually agreed upon by McDATA and SCI. Level 2 and 3 Failures are included ix xxxxe weekly reports. b. SCI shall provide proof that delivered Product meets all requirements including the successful completion of all inspections and tests. c. SCI shall report Failure Analysis queue levels on a weekly basis, including quantity in each troubleshoot location and aging of the items in each location.
Sample 1
Reporting and Data. Commencing on the Effective Date: a. SUPPLIER shall provide weekly reports of process quality performance, including yield, defect pareto, root cause, and corrective actions. Process steps to be included in the reports are to be mutually agreed upon by Dot Hill and SUPPLIER. Level 2 and 3 Failures are included in these weekly reports. b. SUPPLIER shall provide proof that delivered Product meets all requirements including the successful completion of all inspections and tests. c. SUPPLIER shall report Failure Analysis queue levels on a weekly basis, including quantity in each troubleshoot location and aging of the items in each location.
Sample 1
Reporting and Data 
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs

Related to Reporting and Data

  • Information and Data ‌ Upon request of the Union, the Employer agrees to furnish the Union with the following information: budgets for the Board of Regents; budgets for each College; public information used in the preparation of budgets as provided by law such as salaries; minutes of meetings of the Board; policies of the Board of Regents which apply to faculty members. Voluminous information shall be made available for inspection or will be provided at reproduction cost.

  • Monitoring and Reporting The Programme Operator shall monitor, record and report on progress towards the programme’s outcomes in accordance with the provisions contained in the legal framework. The Programme Operator shall ensure that suitable and sufficient monitoring and reporting arrangements are made with the project promoters in order to enable the Programme Operator and the NFP to meet its obligations to the donors. When reporting on progress achieved in Annual and Final Programme Reports, the Programme Operator shall disaggregate results achieved as appropriate and in accordance with instructions and templates received from the FMO.

  • Information and Reporting The Adviser shall provide the Trust and its respective officers with such periodic reports concerning the obligations the Adviser has assumed under this Agreement as the Trust may from time to time reasonably request.

  • Research Use Reporting To assure adherence to NIH GDS Policy, the PI agrees to provide annual Progress Updates as part of the annual Project Renewal or Project Close-out processes, prior to the expiration of the one (1) year data access period. The PI who is seeking Renewal or Close-out of a project agree to complete the appropriate online forms and provide specific information such as how the data have been used, including publications or presentations that resulted from the use of the requested dataset(s), a summary of any plans for future research use (if the PI is seeking renewal), any violations of the terms of access described within this Agreement and the implemented remediation, and information on any downstream intellectual property generated from the data. The PI also may include general comments regarding suggestions for improving the data access process in general. Information provided in the progress updates helps NIH evaluate program activities and may be considered by the NIH GDS governance committees as part of NIH’s effort to provide ongoing stewardship of data sharing activities subject to the NIH GDS Policy.

  • Project Monitoring Reporting and Evaluation The Recipient shall furnish to the Association each Project Report not later than forty-five (45) days after the end of each calendar semester, covering the calendar semester.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!